Cryptococcal meningitis: Current approaches to management in patients with and without AIDS

被引：9

作者：

Brizendine K.D. ^{[1
]}

Pappas P.G. ^{[1
]}

机构：

[1] Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294-0006, THT 229

来源：

Current Infectious Disease Reports | 2010年 / 12卷 / 4期

关键词：

Cryptococcal meningitis; Cryptococcal meningoencephalitis; Cryptococcosis; Cryptococcus; Cryptococcus gattii; Cryptococcus neoformans;

D O I：

10.1007/s11908-010-0113-4

中图分类号：

学科分类号：

摘要：

Cryptococcal meningitis is a life-threatening fungal infection of the central nervous system (CNS). Its management is characterized by the administration of initial combination antifungal therapy by following the principles of induction, consolidation, and maintenance therapy with aggressive management of elevated intracranial pressure (ICP). These tenets apply to patients with and without AIDS. Recent prospective trials on combination antifungal therapy, and the timing of the initiation of highly active antiretroviral therapy (HAART), suggest amphotericin B plus flucytosine and initiation of HAART are optimal therapy for management of patients with AIDS and cryptococcal meningitis. The paucity of prospective data on the management of cryptococcal meningitis in patients without AIDS is the most challenging aspect of formulating treatment guidelines, but the principles of induction, consolidation, and maintenance still apply. Combination antifungal therapy with a lipid formulation of amphotericin B plus flucytosine is generally indicated for this group, especially for those with a predisposition to renal dysfunction. Future research targeting this population may further inform recommendations. © 2010 Springer Science+Business Media, LLC.

引用

页码：299 / 305

页数：6

共 29 条

[1]

Lortholary O., Poizat G., Zeller V., Et al., Long term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy, AIDS, 20, pp. 2183-2191, (2006)

[2]

Park B.J., Wannemuehler K.A., Marston B.J., Et al., Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS, AIDS, 23, pp. 525-530, (2009)

[3]

Perfect J.R., Dismukes W.E., Dromer F., Et al., Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America, Clin Infect Dis, 50, pp. 291-322, (2010)

[4]

Van Der Horst C.M., Saag M.S., Cloud G.A., Et al., Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome, N Engl J Med, 337, pp. 15-21, (1997)

[5]

Saag M.S., Powderly W.G., Cloud G.A., Et al., Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group, N Engl J Med, 326, pp. 83-89, (1992)

[6]

Brouwer A.E., Rajanuwong A., Chierakul W., Et al., Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomized trial, Lancet, 363, pp. 1764-1767, (2004)

[7]

Robinson P.A., Bauer M., Leal M.A., Et al., Early mycological treatment failure in AIDS-associated cryptococcal meningitis, Clin Infect Dis, 28, pp. 82-92, (1999)

[8]

Bicanic T., Wood R., Meintjes G., Et al., High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial, Clin Infect Dis, 47, pp. 123-130, (2008)

[9]

Bicanic T., Muzoora C., Brouwer A.E., Et al., Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: Analysis of a combined cohort of 262 patients, Clin Infect Dis, 49, pp. 702-709, (2009)

[10]

Dromer F., Bernede-Bauduin C., Guillemot D., Lortholary O., Major role for amphotericin B-flucytosine combination in severe cryptococcosis, PLoS ONE, 3, pp. 1-9, (2008)

← 1 2 3 →